TNFSF11 and prostate carcinoma: Denosumab, a humanized monoclonal RANKL antibody, which could play a crucial role in different physiological activity including the prevention of skeletal-related events arising from cancer [28], was FDA approved for breast cancer, prostate cancer and so on [29], but had not been studied in endometrial cancer.